Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by gram-negative bacteria: Results from a randomized clinical study

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3819-3825

  Spyridaki, Aikaterini ^a   Raftogiannis, Maria ^a   Antonopoulou, Anastasia ^a   Tsaganos, Thomas ^a   Routsi, Christina ^a   Baziaka, Fotini ^a   Karagianni, Vassiliki ^a   Mouktaroudi, Maria ^a   Koutoukas, Pantelis ^a   Pelekanou, Aimilia ^a   Kotanidou, Anastasia ^a   Orfanos, Stylianos E ^a   Van Der Meer, Jos W M ^b   Netea, Mihai G ^b   Giamarellos Bourboulisa, Evangelos J ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD40 LIGAND; CD86 ANTIGEN; CLARITHROMYCIN; HYDROCORTISONE; INTERLEUKIN 10; INTERLEUKIN 6; PLACEBO; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CELL ISOLATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; HUMAN; IMMUNOPHENOTYPING; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; MONOCYTE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEPTIC SHOCK; STATISTICAL SIGNIFICANCE; VENTILATOR ASSOCIATED PNEUMONIA;

ANTIGENS, CD86; APOPTOSIS; CD40 LIGAND; CLARITHROMYCIN; DOUBLE-BLIND METHOD; GRAM-NEGATIVE BACTERIA; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; PNEUMONIA, VENTILATOR-ASSOCIATED; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862557241     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05798-11     Document Type: Article

References (20)

1. Ding Y, et al. 2004. Polymicrobial sepsis induces divergent effects on splenic and peritoneal dendritic cell function in mice. Shock 22:137-144.
2. Giamarellos-Bourboulis EJ. 2010. What is the pathophysiology of the septic host upon admission? Int. J. Antimicrob. Agents 36(Suppl 2):S2-S5. doi:10.1016/j.ijantimicag.2010.11.003.
3. Giamarellos-Bourboulis EJ, et al. 2006. Early apoptosis of blood monocytes in the septic host: is it a mechanism of protection in the event of septic shock? Crit. Care 10:R76. doi:10.1186/cc4921.
4. Giamarellos-Bourboulis EJ, et al. 2008. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin. Infect. Dis. 46:1157-1164.
5. Giamarellos-Bourboulis EJ, et al. 2011. Inhibition of caspase-1 activation in Gram-negative sepsis and experimental endotoxemia. Crit. Care 15:R27. doi:10.1186/cc9974.
6. Gibot S, et al. 2004. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J. Exp. Med. 200:1419-1426.
7. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. 2000. Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J. Infect. Dis. 181:176-180.
8. Hellenic Sepsis Study Group. 2010. Presentation May 7, 2010. Hellenic Sepsis Study Group, Greece. www.sepsis.gr.
9. Heron M. 2007. Deaths: leading causes for 2004. Natl. Vital Stat. Rep. 56:1-95.
10. Lanier LL, et al. 1995. CD80 (B7-1) and CD86 (B7-2) provide similar co-stimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J. Immunol. 154:97-105.
11. Newton S, et al. 2004. Sepsis-induced changes in macrophage costimulatory molecule expression: CD86 as a regulator of anti-inflammatory IL-10 response. Surg. Infect. (Larchmt.) 5:375-383.
12. Nolan A, et al. 2009. 2009. Differential role for CD80 and CD86 in the regulation of the innate immune response in murine polymicrobial sepsis. PLoS One 4:e6600. doi:10.1371/journal.pone.0006600.
13. Poukoulidou T, et al. 2011. TREM-1 expression on neutrophils and monocytes of septic patients: relation to the underlying infection and the implicated pathogen. BMC Infect. Dis. 11:309. doi:10.1186/1471-2334-11-309.
14. Remick DG. 2007. Pathophysiology of sepsis. Am. J. Pathol. 170:1435-1444.
15. Rittisch D, Flierl MA, Ward PA. 2008. Harmful molecular mechanisms in sepsis. Nat. Immunol. 8:776-786.
16. Sáenz JJ, Izura JJ, Manrique A, Sala F, Gaminde I. 2001. Early prognosis in severe sepsis via analyzing the monocyte immunophenotype. Intensive Care Med. 27:970-977.
17. Sinistro A, et al. 2008. Downregulation of CD40 ligand response in monocytes from sepsis patients. Clin. Vaccine Immunol. 15:1851-1858.
18. Tesarz AS, Cerwenka A. 2008. The TREM-1/DAP12 pathway. Immunol. Let. 116:111-116.
19. Togami K, Chono S, Morimoto K. 2011. Distribution characteristics of clarithromycin and azithromycin, macrolide antimicrobial agents used for the treatment of respiratory infections, in lung epithelial lining fluid and alveolar macrophages. Biopharm. Drug Dispos. 32:389-397.
20. Vincent JL, Sun Q, Dubois MJ. 2002. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin. Infect. Dis. 34:1084-1093.